Skip to content
value.today
AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is listed today as AN2 Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of AN2 Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2026$40 MPrivate placement after listing$10 to $50 million

AN2 Therapeutics, Inc.: Private sale, Mar 2026

Investors in this round

16 investors had bought by the notice of Mar 25, 2026: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for AN2 Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,400,003
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric Easom · Executive Officer, Director
  • Joshua Eizen · Executive Officer
  • Lucy Day · Executive Officer
  • Sanjay Chanda · Executive Officer
  • Gilbert Lynn Marks · Director
  • Joseph S. Zakrzewski · Director
  • Kabeer S. Aziz · Director
  • Margaret Lynn FitzPatrick · Director
  • Melvin Lynn Spigelman · Director
  • Patricia Lynn Martin · Director
  • Rob S. Readnour · Director
  • Stephanie Lynn Wong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Leerink Partners LLC (CRD 39011) · Boston, MassachusettsSold in AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY

Signed by Eric Easom, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 25, 2026. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • AN2 Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2026).

    SEC Form D · Mar 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2026

That is all the official record says: AN2 Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of AN2 Therapeutics, Inc. are on record.

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in AN2 Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Adjuvant Capital GP, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Adjuvant Capital Management, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Adjuvant Global Health Technology Fund DE, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Adjuvant Global Health Technology Fund, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Eric EasomPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2022)SEC Form 3
Joseph S. ZakrzewskiPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2022)SEC Form 3
RA Capital Healthcare Fund LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Ra Capital Management, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
RA Capital Nexus Fund II, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding AN2 Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by AN2 Therapeutics, Inc.
NameRoleNamed in
Eric EasomExecutive officerMar 2026
Joshua EizenExecutive officerMar 2026
Lucy DayExecutive officerMar 2026
Sanjay ChandaExecutive officerMar 2026
Eric EasomDirectorMar 2026
Gilbert Lynn MarksDirectorMar 2026
Joseph S. ZakrzewskiDirectorMar 2026
Kabeer S. AzizDirectorMar 2026
Margaret Lynn FitzPatrickDirectorMar 2026
Melvin Lynn SpigelmanDirectorMar 2026
Patricia Lynn MartinDirectorMar 2026
Rob S. ReadnourDirectorMar 2026
Stephanie Lynn WongDirectorMar 2026

Went public since 2022. Its SEC number is that of a company listed on a stock exchange.